Proceedings of the Second Update on Psoriatic Disease
University Federico II Congress Center
Naples, Italy
July 6–7, 2011

Foreword: Second Update on Psoriatic Disease
J.M.H. Moll ................................................................. 1

New Insights into the Concept of Psoriatic Disease
R. Scarpa ................................................................. 4

Pathogenetic Overview of Psoriatic Disease
M. Haroon, O. FitzGerald ................................. 7

The Synovio-enthesal Complex and Its Role in Tendon and Capsular
Associated Inflammation

Th17 and IL-23 in the Pathogenesis of PsA and SpA
A. Cauli, A. Mathieu ........................................... 15

Remission in PsA A. Caperon, P.S. Helliwell ........ 19

New Insights in Occult PsA
C. Palazzi, S. D’Angelo, E. Lubrano, I. Olivieri .... 22

Metabolic Syndrome in Patients with Psoriatic Disease
J.M. Gelfand, H. Yeung ........................................ 24

Entheseal Power Doppler Ultrasonography: A Comparison of PsA and
Fibromyalgia
A. Marchesoni, O. De Lucia, L. Rotunno, G. De Marco, M. Manara .............................. 29

Mortality and Causes of Death in PsA
R. Arumugam, N.J. McHugh ............................... 32

Osteoporosis and PsA

PsA: Need for Ultrasound in Everyday Clinical Practice
W. Grassi, M. Gutierrez ................................. 39

Dynamic Contrast-enhanced MRI of Articular and Extraarticular Synovial
Structures of the Hands in Patients with PsA
M.A. Cimmino, F. Barbieri, M. Boesen, et al .... 44

New Developments in MRI of the Nail Unit
E. Soscia, C. Sirignano, O. Catalano, et al ........... 49

The Radiological Assessment of Axial Involvement in PsA
E. Lubrano, A. Marchesoni, I. Olivieri, et al ........ 54

Biomarker Development in PsA C. Ritchlin ..................... 57

Contents continued on back cover . . .
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synovial Biomarkers in PsA</td>
<td>61</td>
</tr>
<tr>
<td>Soluble Biomarkers May Differentiate Psoriasis from PsA</td>
<td>65</td>
</tr>
<tr>
<td>The Actual Role of Therapy with Traditional DMARD in PsA</td>
<td>67</td>
</tr>
<tr>
<td>Infliximab in PsA</td>
<td>71</td>
</tr>
<tr>
<td>Etanercept in PsA</td>
<td>74</td>
</tr>
<tr>
<td>Adalimumab in PsA</td>
<td>77</td>
</tr>
<tr>
<td>Screening and Monitoring of Latent Tubercular Infection in Patients Taking TNF-α Blockers for PsA</td>
<td>82</td>
</tr>
<tr>
<td>Ustekinumab for Psoriasis and PsA</td>
<td>86</td>
</tr>
<tr>
<td>Treatment of PsA with TNF Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL)</td>
<td>90</td>
</tr>
<tr>
<td>Should We Consider TNF as the Only Target in Spondyloarthritides?</td>
<td>94</td>
</tr>
<tr>
<td>IL-6 Blockade: Tocilizumab in PsA</td>
<td>97</td>
</tr>
<tr>
<td>The Inhibitor of Costimulation of T Cells: Abatacept</td>
<td>100</td>
</tr>
<tr>
<td>Pharmacoeconomic Issues in PsA</td>
<td>103</td>
</tr>
<tr>
<td>Future Trends in Research in PsA</td>
<td>106</td>
</tr>
</tbody>
</table>